Clinical and microbiological profile of infectious keratitis in an area of Madrid, Spain

Lin, 2005, The fixed combination of fortified vancomycin and amikacin ophthalmic solution—VA solution in vitro study of the potency and stability, Cornea, 24, 717, 10.1097/01.ico.0000154231.10994.6d

Karampatakis, 2009, Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus, Acta Ophthalmol, 87, 555, 10.1111/j.1755-3768.2008.01306.x

Chang, 2015, Antibiotic resistance in the treatment of Staphylococcus aureus keratitis: a 20-year review, Cornea, 34, 698, 10.1097/ICO.0000000000000431

Hsiao, 2016, Shifting trends in bacterial keratitis in Taiwan: a 10-year review in a Tertiary-Care Hospital, Cornea, 35, 7, 10.1097/ICO.0000000000000734

Sharma, 2016, Gatifloxacin 0.3% versus fortified tobramycin–cefazolin in treating nonperforated bacterial corneal ulcers: randomized, controlled trial, Cornea, 35, 56, 10.1097/ICO.0000000000000664

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Available from: http://www.eucast.org.

https://www.ibm.com/analytics/us/en/technology/spss/.

Hernandez-Camarena, 2015, Trends in microbiological and antibiotic sensitivity patterns in infectious keratitis: 10-year experience in Mexico City, Cornea, 34, 778, 10.1097/ICO.0000000000000428

Willcox, 2011, Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins, Clin Exp Optom, 94, 8, 10.1111/j.1444-0938.2010.00536.x

Sotozono, 2002, Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea, Cornea, 21, S94, 10.1097/01.ico.0000263127.84015.3f

Maple, 1989, World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus, Lancet, 1, 537, 10.1016/S0140-6736(89)90076-7

Cimolai, 1997, Ciprofloxacin and multiresistant staphylococci, Lancet, 349, 1030, 10.1016/S0140-6736(05)62935-2

Maffett, 1993, Ciprofloxacin-resistant bacterial keratitis, Am J Ophthalmol, 115, 6, 10.1016/S0002-9394(14)74467-8

Elsahn, 2010, In vitro susceptibility patterns of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococcus corneal isolates to antibiotics, Cornea, 29, 5, 10.1097/ICO.0b013e3181d2ce25

Miller, 2013, Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci, J Ocul Pharmacol Ther, 29, 339, 10.1089/jop.2012.0081

Goodman, 1988, Methicillin-resistant Staphylococcus epidermidis keratitis treated with vancomycin, Arch Ophthalmol, 106, 1, 10.1001/archopht.1988.01060140738046

Fleischer, 1986, Topical vancomycin formulation for methicillin-resistant Staphylococcus epidermidis blepharoconjunctivitis, Am J Ophthalmol, 101, 7, 10.1016/0002-9394(86)90820-2

Cahane, 2004, Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin, Br J Ophthalmol, 88, 22, 10.1136/bjo.88.1.22

Ramakrishnan, 2010, Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test, Indian J Pathol Microbiol, 53, 276, 10.4103/0377-4929.64337

Morrissey, 2004, Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone, gatifloxacin and other antimicrobials in Europe during 2001/2002, J Infect, 49, 109, 10.1016/j.jinf.2004.03.007

Kaye, 2010, Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis, Invest Ophthalmol Vis Sci, 51, 8, 10.1167/iovs.09-3933

Sy, 2012, Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment, Invest Ophthalmol Vis Sci, 53, 267, 10.1167/iovs.11-7840

Jain, 2014, Use of topical colistin in multiple drug-resistant Pseudomonas aeruginosa bacterial keratitis, Cornea, 33, 7, 10.1097/ICO.0000000000000184

Sueke, 2010, An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis, Invest Ophthalmol Vis Sci, 51, 5, 10.1167/iovs.09-4839